Biogen Inc. BIIB NASDAQ

NASDAQ Global Select • Healthcare • Drug Manufacturers - General • US • USD

SharesGrow Score

60/100

2/7 Pass

SharesGrow Intrinsic Value

Il y a eu 50 transactions d'initiés récentes enregistrées pour Biogen Inc. (BIIB), dont 23 achats et 26 ventes. Le total des achats d'initiés s'élève à $152.14K et le total des ventes d'initiés à $2.46M.

Les initiés notables ayant une activité récente comprennent Godbout Sean, Alexander Susan H, Gregory Ginger. Les transactions d'initiés peuvent fournir des indications sur la façon dont la direction perçoit la valorisation et les perspectives futures de l'action.

Transactions d'Initiés — BIIB

Date	Nom	Rôle	Type de Transaction	Actions	Prix Moyen	Valeur	Actions détenues
2026-04-01	Godbout Sean	Chief Accounting Officer	Exercice d'Options (Vente)	181	-	-	364
2026-02-13	Alexander Susan H	EVP Chief Legal Officer	Attribution de RSU	8,450	-	-	8,450
2026-02-13	Gregory Ginger	EVP, Human Resources	Attribution de RSU	8,025	-	-	8,025
2026-02-13	Kramer Robin	Chief Financial Officer	Attribution de RSU	8,450	-	-	8,450
2026-02-13	Singhal Priya	Head of Development	Attribution de RSU	10,560	-	-	10,560
2026-02-13	Viehbacher Christopher	President and CEO	Attribution de RSU	38,015	-	-	38,015
2026-02-13	Izzar Rachid	Head of Global Product Strat.	Attribution de RSU	7,390	-	-	7,390
2026-02-13	Murphy Nicole	Head of Pharm Ops and Tech	Attribution de RSU	10,560	-	-	10,560
2026-02-13	Keeney Adam	Head of Corporate Development	Attribution de RSU	8,025	-	-	8,025
2026-02-13	Grogan Jane	Head of Research	Attribution de RSU	8,450	-	-	8,450
2026-02-13	Godbout Sean	Chief Accounting Officer	Attribution de RSU	1,800	-	-	1,800
2026-02-12	Murphy Nicole	Head of Pharm Ops and Tech	Achat Informatif	3	$195.04	$585.11	19,611
2026-02-09	Singhal Priya	Head of Development	Vente Informative	2,660	$199.83	$531.55K	8,043
2026-02-06	Alexander Susan H	EVP Chief Legal Officer	Exercice d'Options (Vente)	2,190	-	-	-
2026-02-06	Gregory Ginger	EVP, Human Resources	Exercice d'Options (Vente)	1,635	-	-	-
2026-02-06	Kramer Robin	Chief Financial Officer	Exercice d'Options (Vente)	789	-	-	-
2026-02-06	Singhal Priya	Head of Development	Exercice d'Options (Vente)	2,217	-	-	2,217
2026-02-06	Viehbacher Christopher	President and CEO	Exercice d'Options (Vente)	9,008	-	-	9,009
2026-02-06	Izzar Rachid	Head of Global Product Strat.	Exercice d'Options (Vente)	2,044	-	-	-
2026-02-06	Murphy Nicole	Head of Pharm Ops and Tech	Exercice d'Options (Vente)	2,102	-	-	-
2026-02-06	Keeney Adam	Head of Corporate Development	Exercice d'Options (Vente)	1,802	-	-	1,802
2026-02-06	Grogan Jane	Head of Research	Exercice d'Options (Vente)	1,385	-	-	1,385
2026-02-06	Godbout Sean	Chief Accounting Officer	Exercice d'Options (Vente)	257	-	-	-
2026-02-02	Singhal Priya	Head of Development	Vente Informative	748	$179.30	$134.12K	6,271
2026-01-30	Singhal Priya	Head of Development	Exercice d'Options (Vente)	1,829	-	-	-
2025-12-01	Viehbacher Christopher	President and CEO	Exercice d'Options (Vente)	7,040	-	-	-
2025-06-17	Sherwin Stephen A	Director	Attribution de RSU	2,370	-	-	13,688
2025-06-17	Hawkins William A	Director	Attribution de RSU	2,370	-	-	8,860
2025-06-17	Dorsa Caroline	Director	Attribution de RSU	3,160	-	-	31,002
2025-06-17	Rowinsky Eric K	Director	Attribution de RSU	2,370	-	-	24,339
2025-06-17	Freire Maria C	Director	Attribution de RSU	2,370	-	-	6,815
2025-06-17	Mantas Jesus B	Director	Attribution de RSU	2,370	-	-	9,758
2025-06-17	Patolawala Monish D	Director	Attribution de RSU	2,370	-	-	3,710
2025-06-17	Langer Susan	Director	Attribution de RSU	2,370	-	-	5,129
2025-06-17	Pangalos Menelas N	Director	Attribution de RSU	2,370	-	-	2,370
2025-06-17	Minor Lloyd	Director	Attribution de RSU	2,370	-	-	2,370
2025-05-19	Singhal Priya	Head of Development	Vente Informative	3,806	$126.25	$480.51K	5,427
2025-05-02	Dorsa Caroline	Director	Achat Informatif	1,235	$122.72	$151.56K	27,842
2025-05-01	Keeney Adam	Head of Corporate Development	Exercice d'Options (Vente)	938	-	-	939
2025-04-01	Godbout Sean	Chief Accounting Officer	Attribution de RSU	545	-	-	545
2025-03-07	Sherwin Stephen A	Director	Vente Informative	8,760	$150.02	$1.31M	11,318
2025-03-01	Godbout Sean	Chief Accounting Officer	Inconnu	257	-	-	-
2025-02-10	Mcdonnell Michael R	EVP, Chief Financial Officer	Exercice d'Options (Vente)	3,257	-	-	-
2025-02-10	Alexander Susan H	EVP Chief Legal Officer	Exercice d'Options (Vente)	2,575	-	-	-
2025-02-10	Gregory Ginger	EVP, Human Resources	Exercice d'Options (Vente)	2,159	-	-	-
2025-02-10	Kramer Robin	Chief Accounting Officer	Exercice d'Options (Vente)	834	-	-	-
2025-02-10	Singhal Priya	Head of Development	Exercice d'Options (Vente)	1,212	-	-	-
2025-02-10	Izzar Rachid	Head of Global Product Strat.	Exercice d'Options (Vente)	1,515	-	-	-
2025-02-10	Murphy Nicole	Head of Pharm Ops and Tech	Exercice d'Options (Vente)	2,272	-	-	-
2025-02-07	Mcdonnell Michael R	EVP, Chief Financial Officer	Exercice d'Options (Vente)	2,335	-	-	2,335

■ Informatif — transaction sur marché ouvert (la plus significative) ■ Non informatif (achat) — récompense, exercice d'option, conversion ■ Non informatif (vente) — retenue fiscale, vente à l'acquisition ■ Neutre — don, fiducie, expiration